Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse <6 months from end o...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Am J Hematol
Hoofdauteurs: Costa, Luciano J., Maddocks, Kami, Epperla, Narendranath, Reddy, Nishitha M., Karmali, Reem, Umyarova, Elvira, Bachanova, Veronika, Costa, Cristiana, Glenn, Martha J., Chavez, Julio C., Calzada, Oscar, Lansigan, Frederick, Nasheed, Hossain, Barta, Stefan K., Zhou, Zheng, Jaglal, Michael, Chhabra, Saurabh, Hernandez-Ilizaliturri, Francisco, Xavier, Ana C., Mehta, Amitkumar, Peker, Deniz, Forero-Torres, Andreas, Al-Mansour, Zeina, Evens, Andrew M., Cohen, Jonathon B., Flowers, Christopher R., Fenske, Timothy S., Hamadani, Mehdi
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5549936/
https://ncbi.nlm.nih.gov/pubmed/27880984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24615
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items